Haematology-Oncology · Clinical trials
Hairy Cell Leukaemia Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About hairy cell leukaemia — and why its trials are hard
Hairy cell leukaemia (HCL) is a rare, indolent B-cell malignancy defined by small lymphocytes with characteristic cytoplasmic projections that infiltrate bone marrow, spleen, and blood, causing pancytopenia and splenomegaly. The near-universal BRAF V600E mutation is a defining molecular hallmark and a therapeutic target. First-line therapy is a single course of a purine nucleoside analogue—cladribine or pentostatin—which produces high rates of durable complete remission and long relapse-free survival; these remain the standard of care decades after introduction. Rituximab is widely used, often combined with cladribine, to deepen responses and clear minimal residual disease. For relapsed or refractory disease, two targeted options emerged: moxetumomab pasudotox, a CD22-directed immunotoxin approved in 2018, and BRAF inhibition with vemurafenib (typically with rituximab) exploiting the BRAF V600E mutation. Endpoints centre on complete remission, durability of response, and minimal residual disease negativity. Overall prognosis is excellent, with near-normal life expectancy for many patients, though a more aggressive variant (HCL-v, lacking BRAF V600E) responds poorly to purine analogues.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Cladribine (2-CdA) (Leustatin) | 1993 | First-line HCL; single short course | Landmark single-arm studies (Piro/Scripps; long-term follow-up cohorts) | Complete remission rate; relapse-free survival | Complete remission ~75-90% after one course; durable multi-year remissions, many lasting >10 years |
| Pentostatin (deoxycoformycin) (Nipent) | 1991 | First-line HCL (purine analogue alternative to cladribine) | Randomised Intergroup trial vs interferon-alfa | Complete remission rate | Complete remission ~76% vs ~11% with interferon; high durable response rates |
| Moxetumomab pasudotox (Lumoxiti) | 2018 | Relapsed/refractory HCL after >=2 prior lines including a purine analogue | Pivotal single-arm study 1053 (Kreitman et al.) | Durable complete response (CR with hematologic remission >180 days) | Durable CR ~30%; overall response ~75%; risk of capillary leak syndrome and haemolytic uraemic syndrome |
| Vemurafenib (BRAF inhibitor, often +rituximab) (Zelboraf) | Used off-label/guideline-supported for BRAF V600E HCL | Relapsed/refractory HCL | Italian and US phase II studies; vemurafenib+rituximab study (Tiacci et al., NEJM) | Complete remission rate | Vemurafenib monotherapy CR ~35-40%; with rituximab CR ~87% and high MRD-negativity |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in hairy cell leukaemia development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Interferon-alfa (historical standard) — Intergroup randomised trial vs pentostatin | Far lower complete-remission rate and shorter durability than purine analogues | Superseded once cladribine/pentostatin showed markedly deeper, more durable remissions |
| Purine analogues in HCL variant (HCL-v) — Case series/cohorts | Poor and short-lived responses in the BRAF-wild-type variant | Distinct biology (no BRAF V600E, often TP53/MAP2K1 alterations); requires different approaches |
Choosing the right endpoint
Primary endpoints that matter in hairy cell leukaemia trials
- Complete remission (CR) — Primary efficacy endpoint; purine analogues achieve very high CR rates with a single course
- Durable complete response — CR maintained beyond a defined interval (e.g., >180 days); primary endpoint for moxetumomab pasudotox
- Relapse-free / progression-free survival — Measures durability; remissions after cladribine frequently last many years
- Minimal residual disease (MRD) negativity — Deeper endpoint associated with longer remission; driver for adding rituximab or BRAF-targeted therapy
- Hematologic recovery — Normalisation of blood counts and resolution of splenomegaly; clinically meaningful outcome
How iNGENū runs hairy cell leukaemia trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Hairy Cell Leukaemia clinical trials — FAQs
What is the first-line treatment for hairy cell leukaemia?
What role does the BRAF V600E mutation play?
What options exist if the disease relapses?
Ready to discuss your hairy cell leukaemia trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal